Colorectal Cancer

Latest News

July 23rd 2015

Importance of Mismatched Repair Testing in CRC

James J. Lee, MD, PhD, assistant professor of medicine, Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, discusses the importance of mismatched repair testing in colorectal cancer (CRC).

July 20th 2015

Efficacy of Blinatumomab Presented in Phase II Ph+ ALL Study

By Silas Inman

July 15th 2015

Proteomic Study in CRC of Paired Tumor Versus Nontumor Tissue May Identify New Biomarkers

By Colin G. Evans, PhD

July 10th 2015

Cathy Eng, MD, FACP: How to Prolong Survival

July 10th 2015

Cathy Eng, MD, FACP: Re-initiating Bevacizumab After Multiple Lines of Treatment

Latest Videos

Advanced Colorectal Cancer with Marwan G. Fakih, MD Case 1

Dosing Strategies with Trifluridine/Tipiracil

The Role of Trifluridine/Tipiracil in Advanced CRC

Goals of Therapy in Third-Line CRC

Factors Associated With Discordance in Mutation Status in Metastatic CRC

$Relapsed refractory colorectal cancer Case 2$

Relapsed refractory colorectal cancer Case 2

Monitoring for Response and Side Effects in Advanced CRC

Risk of Recurrence in Stage 3B CRC

$Relapsed refractory colorectal cancer Case 1$

Relapsed refractory colorectal cancer Case 1

Dosing and Side Effect Management with Trifluridine/Tipiracil

CME Content

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Rocky Mountain Oncology Society

Seth A. Wander, MD, PhD; Kara M. Schenk, MD

Video

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Patrick I. Borgen, MD; Joshua Feinberg, MD; Gary Schwartz, MD, FASA

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | North Carolina Oncology Association

Marla D. Lipsyc-Sharf, MD; Yan Ji, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Kimberly Ku, MD

Video

43rd Annual Miami Breast Cancer Conference®

Patrick I. Borgen, MD; Reshma Jagsi, MD, DPhil; Hope S. Rugo, MD, FASCO

Multimedia

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Patrick I. Borgen, MD; E. Shelley Hwang, MD, MPH; Mark E. Robson, MD

Multimedia

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Heather McArthur, MD, MPH; Komal Jhaveri, MD, FACP; Sara Tolaney, MD, MPH; Seth A. Wander, MD, PhD

Multimedia

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Rita Nanda, MD; William Gradishar, MD, FASCO, FACP; Komal Jhaveri, MD, FACP; Kevin Kalinsky, MD, MS

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Multimedia

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Hope S. Rugo, MD, FASCO; Sara Hurvitz, MD, FACP; Jennifer Litton, MD, MHCM; Heather McArthur, MD, MPH

Multimedia

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Joyce O’Shaughnessy, MD; William Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH; Eleni Anastasia Tousimis, MD, MBA, FACS

In-Person Event

Immune Therapies in Practice in 2026: Cellular Therapies, ADCs, Bispecifics, and Beyond

May 22, 2026

Multimedia

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Video

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Multimedia

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Multimedia

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Multimedia

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Multimedia

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Multimedia

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Video

24th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

Multimedia

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Video

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

More News

Cathy Eng, MD, FACP: Second EGFR-Directed Therapy and Mutational Status

July 10th 2015

Alan Venook, MD: How to prolong survival

July 10th 2015

Alan Venook, MD: Re-initiating bevacizumab after multiple lines of treatment

July 10th 2015

Alan Venook, MD: Second EGFR-directed therapy and mutational status

July 10th 2015

Alan Venook, MD: Fourth-line treatment for progressive disease

July 10th 2015

Ki Chung, MD: How to Prolong Survival

July 10th 2015

Ki Chung, MD: Re-initiating Bevacizumab After Multiple Lines of Treatment

July 10th 2015

Ki Chung, MD: Second EGFR-Directed Therapy and Mutational Status

July 10th 2015

Ki Chung, MD: Fourth-Line Treatment for Progressive Disease

July 10th 2015

Metastatic Colorectal Cancer: Part 2

July 10th 2015

Metastatic Colorectal Cancer

Cathy Eng, MD, FACP: Second-Line Options to Prolong Survival

July 10th 2015

Cathy Eng, MD, FACP: Continuation of Anti-Angiogenesis Therapy

July 10th 2015

Cathy Eng, MD, FACP: EGFR-Directed Therapy and Mutational Status

July 10th 2015

Cathy Eng, MD, FACP: Impact of Sensory Neuropathy on Second-Line Treatment

July 10th 2015

Alan Venook, MD: Second-Line Options to Prolong Survival

July 10th 2015

Alan Venook, MD: Continuation of Anti-Angiogenesis Therapy

July 10th 2015

Alan Venook, MD: EGFR-Directed Therapy and Mutational Status

July 10th 2015

Alan Venook, MD: Impact of Sensory Neuropathy on Second-Line Treatment

July 10th 2015

Ki Chung, MD: Second-Line Options to Prolong Survival

July 10th 2015

Ki Chung, MD: Continuation of Anti-Angiogenesis Therapy

July 10th 2015

Ki Chung, MD: EGFR-Directed Therapy and Mutational Status

July 10th 2015

Ki Chung, MD: Impact of Sensory Neuropathy on Second-Line Treatment

July 10th 2015

Metastatic Colorectal Cancer: Part 1

July 10th 2015

Metastatic Colorectal Cancer

Prevention and Screening of CRC

ByNadir Arber, MD, MSc, MHA

July 10th 2015

Nadir Arber, MD, MSc, MHA, director of the Integrated Cancer Prevention Center (ICPC), Tel Aviv Sourasky Medical Center, discusses prevention and screening of colorectal cancer (CRC).

Survival Differences in KRAS/BRAF Mutations in mCRC

ByHalfdan Sorbye, MD

July 9th 2015

Halfdan Sorbye, MD, professor, Department of Oncology and Medical Physics, Haukeland University Hospital, University of Bergen, discusses the survival differences in KRAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC).